AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
LFST

LifeStance Health Group Inc. Common Stock (LFST) fair value

Healthcare · Medical Care Facilities · NASDAQ · United States
$12.93+2.95%
Market cap $4.8BNext earnings 2026-11-05Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 103% above our fair value
Price
$12.93
Model fair valueConfidence: good
$6.37
Model range
$4.07 to $8.67
Fair value $6.37
Price $12.93
2 models fit LifeStance Health Group Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Large premium(i)Silver66
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionLifeStance Health Group Inc. Common Stock (LFST)
Fair value (2 models)
$6.37
ACCE price target
$13.00
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 18:04 CEST; previously $6.27 since 11 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 18:04 CEST.
Price used: $12.93 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
102.9% above
-50.7% to fair value
ACCE score
65
out of 100
Analysts
82% buy
11 covering
P/E
96.6x
forward 52.6x
1-year return
+151.6%
Dividend yield
0.00%

LifeStance Health Group Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

LifeStance Health operates one of the largest outpatient mental health networks in the US, delivering psychotherapy and psychiatric medication management through employed clinicians and affiliated practices across most states. The model's edge is scale in a fragmented, supply-constrained market where patient demand for behavioral health care has outrun clinician capacity, and the company's platform lets it add providers faster than smaller independents can. Revenue growth of 26.1% is the figure to focus on, showing the network is still expanding its footprint and patient volumes rather than just raising prices. Profitability is early: a 7.2% operating margin and 33.6% gross margin leave room for operating leverage as clinician utilization rises, though a 3.4% ROE and a 95.2 trailing P/E mean the market is paying up for that improvement. At a 52.6 forward P/E the thesis rests on margin expansion arriving on schedule, so the deeper look should test clinician productivity, reimbursement trends and payer mix before anything else.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    Heavy insider selling
    Insiders disclosed $378.79M in sales across the last 10 filings with zero buys, a one-directional signal worth weighing against the $4.7B market cap.
  • moderate
    Rich valuation multiples
    P/E of 95.5 and EV/EBITDA of 36.7 leave little room for error, with operating margin at only 7.2% and net margin at 3.2%.
  • moderate
    Elevated short interest
    Short interest stands at 8.5% of float, meaning a meaningful minority of holders are betting on the shares falling.

AI research notes

AI-assisted·How I use AIWritten Oct 13, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 26.1% over the last year, and has averaged 30.4% a year over five years.
  • The company beat expected earnings per share, reporting $0.06 against $0.03 forecast.
Why it could disappoint
  • The share price of $12.48 sits about twice the consensus fair value of $6.27, a gap of 49.8%.
  • At 52.6 times forward earnings, the stock is priced far above the sector median of 23.6 times.
  • Return on invested capital is just 0.5%, and net margin is only 3.2%, so profits are thin for the money invested.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where LFST's valuation models land
Price
$12.93
Model fair value
$6.37
Model range
$4.07 to $8.67
Fair value $6.37
Price $12.93
The price is above the whole model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish82% buy · 11 covering analysts
● Strong buy 7● Buy 2● Hold 2● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+10.1%
1 month
+7.0%
3 months
+18.6%
6 months
+83.4%
YTD
+83.7%
1 year
+151.6%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 18:04 CESTRatingOvervaluedfirst publication$11.74
19 Oct 2026, 18:04 CESTFair value$6.37$6.27$11.74
11 Oct 2026, 00:00 CESTACCE price target$13.00first publication$12.42
11 Oct 2026, 00:00 CESTFair value$6.27$2.38$12.42
7 Oct 2026, 00:00 CESTFair value$2.38$2.31$12.22
4 Oct 2026, 00:00 CESTFair value$2.31$2.35$11.83
28 Sept 2026, 00:00 CESTFair value$2.35$2.29$11.84
25 Sept 2026, 00:00 CESTFair value$2.29$2.38$12.08
21 Sept 2026, 00:00 CESTFair value$2.38$2.33$12.57
18 Sept 2026, 00:00 CESTFair value$2.33$2.43$12.79

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full LFST page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth88Value25Quality51Momentum97Total65
Valuation
Trailing P/E
96.6x
Forward P/E
52.6x
PEG
0.05
P/B
3.11x
EV / Revenue
3.0x
Book value/sh
$3.87
Enterprise value
$4.8B
Profitability
ROE
3.4%
FCF yield
2.30%
ROIC
0.5%
Health and risk
Debt / equity
0.13
Dividend yield
0.00%
Beta
1.24

Price

+148.7% · 1Y

Ask anything about LFST

Answered from LifeStance Health Group Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 17% of peers
low 23.7x96.6xhigh 104.5x
ROEbetter than 0% of peers
low 3%3%high 47%
Div yieldbetter than 17% of peers
low 0.0%0.0%high 1.1%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
LFST LifeStance Health Group Inc. Common Stock$12.93$6103% above96.6x3.4%5165
OPCH Option Care Health Inc. Common Stock$31.22$348% below23.7x16.0%4858
CON Concentra Group Holdings Parent Inc. Common Stock$39.25$2747% above25.3x47.1%6474
MCOV-B.ST Medicover AB (publ)kr 276.00kr 17657% above45.2x15.5%4354
FORTIS.NS Fortis Healthcare Limited₹712.90--51.4x-7645
ASTERDM.NS Aster DM Quality Care Limited₹644.75--104.5x-7144
NHC National HealthCare Corporation$236.01$236At fair value27.3x13.3%6877

Sector report card

Where LFST ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 15, 2026
    LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
  • PR Newswire•Sep 30, 2026
    Nearly Half of Americans Say Fear of an Unwanted Viral Moment Keeps Them from Being Themselves in Public, LifeStance Survey Finds
  • GlobeNewswire•Sep 9, 2026
    LifeStance Health Group Announces Pricing of Secondary Public Offering
3 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 16
8-KCurrent reportPeriod 2026-10-14
View on SEC →
September 2026
Sep 24
Form 4Insider transactionPeriod 2026-09-22
View on SEC →
Sep 15
Form 4Insider transactionPeriod 2026-09-11
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR